BGI Genomics Empowers Middle East Healthcare with Precision Medicine

BGI Genomics Bahrain Iran Iraq Jordan Kuwait Lebanon Oman Palestine Qatar Saudi Arabia Syria United Arab Emirates Yemen

State of Colorectal Cancer Awareness Report 2023 shows that 62.7% of Saudi Arabian respondents never took CRC tests, far higher than the global average of 54.1%.

BGI Genomics 2023 Global State of Colorectal Cancer Awareness Report reveals 62.7% of Saudi Arabian respondents never had a CRC screening

To address these problems, Genalive offers COLOTECT™, a non-invasive and accessible colorectal cancer screening test with a high sensitivity rate, aiming to raise awareness and detect disease at an early stage.

As the Kingdom embraces the Belt and Road Initiative (BRI), Dr. Yusra sees immense potential for positive, long-term impact in enhancing health outcomes. To meet the increasing demand for prenatal testing in the Kingdom, Genalive has introduced the NIFTY® test, allowing screening for common trisomies with enhanced safety, accuracy, and a rapid turnaround time.

Dr. Yusra's story is encapsulated by her name, "the person who makes everything easy" in Arabic. Besides her professional endeavors, she cherishes quality time with her family, exploring new places, experiencing diverse cuisines, and providing her two children with compassion and social responsibility.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading provider of integrated solutions for precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676. SZ) was officially listed on the Shenzhen Stock Exchange.

Video - https://mma.prnewswire.com/media/2305053/231219_Saudi_Yusra.mp4
Photo - https://mma.prnewswire.com/media/2305054/Respondents_who_never_had_a_CRC_test.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bgi-genomics-empowers-middle-east-healthcare-with-precision-medicine-302019907.html

@ prnewswire.co.uk